RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer
The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of 'molecular target' therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 2×
“…p21/p27/p57 Cip/Kip family of CDK2:cyclin E inhibitors (Grimison et al., 2000; Jiang et al., 1998; Sherr and Roberts, 1999), seemingly to both sequester inhibitory activity away from CDK2:cyclin E complexes and, perhaps, to stabilize CDK4/6:cyclin D activity (Sherr and Roberts, 1999) (Figure 1).”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“…et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which phosphorylates RB in late G1, suggested that the p16 gene could be an important target for mutations in a wide range of…”
BackgroundA human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 1×
“Nonetheless, shortly after the validation of the RB gene as the locus that underlies the development of both familial and sporadic retinoblastoma (Friend et al., 1986; Lee et al., 1987), mutational inactivation of the RB gene was identified in approximately 90% of the common adult malignancy, small…”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 2×
“The almost simultaneous description of the p16 gene as the locus conferring susceptibility familial melanoma (Kamb et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which…”
BackgroundMost human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114 · cited 1×
“…lung, and thyroid, they are rarely detected in the endocrine tumors that arise from these same organs and may occur in 0% of medullary thyroid cancer and in 0% of neuroendocrine small cell lung cancer (Almoguera et al., 1988; Bockhorn et al., 2000; Capella et al., 1996; Mitsudomi et al., 1991).”
BackgroundMerlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986 · cited 1×
“…in identifying acquired somatic p16 mutations in tumors resulted from the unexpected observation that the p16 gene preferentially undergoes tumor-specific epigenetic gene silencing through promoter and exon 1 hypermethylation (Herman et al., 1995; Merlo et al., 1995; Otterson et al., 1995).”
BackgroundEffects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755 · cited 1×
“For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992).”
BackgroundThe Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis
Lee, E. Y.-H. P., Chang, C.-Y., Hu, N., Wang, Y.-C. J., Lai, C.-C., Herrup, K., Lee, W.-H., & Bradley, A. (1992) · Nature · doi:10.1038/359288a0 · Cited by 1,265 · cited 1×
“For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992).”
Background
Cited by
Items 101–153 of 153
Genetic and Epigenetic Alterations in Cancer
Teh, B. T., & Fearon, E. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00014-1 · Cited by 20
Cecchini, M. J., Ishak, C. A., Passos, D. T., Warner, A., Palma, D. A., Howlett, C. J., Driman, D. K., & Dick, F. A. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.08.010 · Cited by 16
“Lastly, loss of pRB may be incompatible with oncogenic K-Ras under some circumstances [37,38].”
BackgroundIs There Any Association BetweenNek3and Cancers with Frequent 13q14 Deletion?
Hernández, M., & Almeida, T. A. (2006) · Cancer Investigation · doi:10.1080/07357900600981364 · Cited by 11
NIR promotes progression of colorectal cancer through regulating RB
Li, Y., Wang, L., Liu, X., Zhang, C., Du, X., & Xing, B. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118856 · Cited by 9
Molecular Basis of Pulmonary Disease
Farver, C. F., & Zander, D. S. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374419-7.00018-4 · Cited by 13
“Mutations in the RB1 gene exist in many SCLCs, with associated loss of function of the gene product [71,74,85].”
Ding, J., Ge, D., Guo, W., & Lu, C. (2008) · Lung · doi:10.1007/s00408-008-9127-1 · Cited by 9
“It is now well known that abnormalities in many positive and negative modulators of the cell cycle are frequent in many cancer types, including lung carcinomas [12, 13].”
BackgroundPark, Y., Kubo, A., Komiya, T., Coxon, A. B., Beebe, K. E., Neckers, L., Meltzer, P. S., & Kaye, F. J. (2008) · Cell Cycle · doi:10.4161/cc.6363 · Cited by 10
“In addition, we have observed a discordant cellular response in these cells with (1) the loss of cyclin D1 protein and the induction of CDKN2a/ p16 protein, characteristic of RB null cells,13,40 and conversely (2) co-expression of mutant K-ras which is characteristic of RB wt cells and not observed in RB null small-ce…”
BackgroundSelf-citationQi, X., Zhang, Z.-F., Gao, X., Qin, S., Bai, Y., Yu, W., He, Q., Yu, F., Zhang, J., Jiang, Y. Y., et al. (2023) · Translational Andrology and Urology · doi:10.21037/tau-22-867 · Cited by 8
Qiu, X., Liang, Y., Sellers, R. S., Perez-Soler, R., & Zou, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109874 · Cited by 8
RNA-Seq and Network Analysis Revealed Interacting Pathways in TGF-β-Treated Lung Cancer Cell Lines
Li, Y., Rouhi, O., Chen, H., Ramirez, R., Borgia, J. A., & Deng, Y. (2014) · Cancer Informatics · doi:10.4137/cin.s14073 · Cited by 8
Gómez, A. M., Sarceda, J. R. J., García‐Asenjo, J. A. L., Fernández, C., Hernández, S., Sanz‐Ortega, J., Fernández, E., Calatayud, J., Torres, A., & Hernándo, F. (2014) · Tumor Biology · doi:10.1007/s13277-013-1599-9 · Cited by 6
“This finding is in line with the hypothesis proposed by Kaye indicating that most lung cancer samples have an inactivated RB/p16 tumor suppressor pathway [25].”
ResultModeling Cell Cycle Control and Cancer with pRB Tumor Suppressor
Yamasaki, L. (2006) · Springer eBooks · doi:10.1007/b136682 · Cited by 7
Khan, M., Singh, K., Khan, S., Ahmad, B., Khushal, A., & Yingning, S. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2300121 · Cited by 6
“Thus, targeting CDKs is a significant anti-cancer therapy (Kaye, 2002).”
Li, J., Kovach, A. R., DeMonia, M., Slemmons, K. K., Oristian, K. M., Chen, C., & Linardic, C. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-95355-2 · Cited by 6
The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts
Sosa-García, B., Vázquez‐Rivera, V., González-Flores, J., Engel, B. E., Cress, W. D., & Santiago‐Cardona, P. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142406 · Cited by 5
“Of note, Rb function is impaired in most, if not all, lung cancers, whether directly by mutations in the RB1 gene itself or indirectly by mutations in the CDKN2 locus coding for p16INK4a [41, 42], which result in Rb and Osteoblast Cell Adhesion”
BackgroundWatanabe, H., Inoue, Y., Tsuchiya, K., Asada, K., Suzuki, M., Ogawa, H., Tanahashi, M., Watanabe, T., Matsuura, S., Yasuda, K., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00860-6 · Cited by 5
p16 positive oropharyngeal small cell cancer: A case report
Masalmeh, N. A., Kukreja, G., Zaiem, F., Raza, S. N., Kim, H. L., Nagasaka, M., & Sukari, A. W. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105391 · Cited by 4
Malumbres, M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00004-7 · Cited by 6
Chen, R., Tihy, M., Lacroix, L., Rycke, O. D., Lacombe, C., Just, P. A., Cazes, A., Svrcek, M., de Montpréville, V., Antoine, M., et al. (2025) · Endocrine Pathology · doi:10.1007/s12022-025-09885-w · Cited by 3
“A similar mechanism occurs when CCND1 or CCNE1 , encoding cyclins D1 and E1, respectively, are amplified, representing alternative pathways of Rb inactivation leading to uncontrolled cell proliferation [35].”
Genetic and Epigenetic Alterations in Cancer
Fearon, E. R. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00013-8 · Cited by 5
DNA methylation: its role in lung carcinogenesis and therapeutic implications
Santos, E. S., Raez, L. E., DeCesare, T., & Singal, R. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.4.667 · Cited by 3
Expression of cell cycle regulator p16 is not affected by diabetes during oral oncogenesis.
Vairaktaris, E. G., Goutzanis, L., Nkenke, E., Spyridonidou, S., Vassiliou, S., Derka, S., Vylliotis, A., Yapijakis, C., Lazaris, A. C., & Patsouris, E. (2007) · PubMed · Cited by 3
Otsuka, H., Funai, S., Tanaka, A., Hara, S., & Shiozaki, H. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.02.022 · Cited by 2
“Many tumor suppressor genes encode a cell cycle regulator [7,8]; the loss of RB function is involved in the carcinogenesis of small cell lung cancer [12—14].”
BackgroundVolante, M., Sapino, A., Papotti, M., Pacchioni, D., & Bussolati, G. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1069-1_18 · Cited by 2
Selo, M. A., Gobbo, O. L., Obaidi, I., O’Connor, C. M., Fayne, D., Armstrong, M. E., & Donnelly, S. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062829 · Cited by 1
The Retinoblastoma Protein in Osteogenesis and Osteosarcoma Formation
Pedro, G. (2012) · InTech eBooks · doi:10.5772/36712
“Other cancer types such as non-small cell lung carcinomas, melanomas, pancreatic carcinomas and T cell lymphomas show mutational inactivation of the CKI p16 (Kaye, 2002).”
BackgroundGonzález, J. L. L., Yustos, M. A., Martínez, B. M.-A., & Soto, M. Á.-M. (2009) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(09)70562-1 · Cited by 1
Expósito, F., González, J. L. L., Villaverde, R. M., & Álvarez‐Mon, M. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70497-9 · Cited by 1
Molecular Biology and Genetics of Lung Cancer
Martin, N. E., Hahn, S. M., & McKenna, W. G. (2005) · Springer eBooks · doi:10.1007/3-540-26632-1_1 · Cited by 3
Gene Therapy and Oncolytic Viruses
Tamgüney, T., Korn, W. M., & McCormick, F. P. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00054-8 · Cited by 1
Proibitina e a resposta a mecanismos de estresse em melanoma e sua relação com a via E2F1
Tortelli, T. C. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2013.tde-14082013-150136 · Cited by 1
Silva, G. R. O. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2019.tde-07052019-103754 · Cited by 3
Rb Inactivation Leads to E2F1-mediated DNA Double Strand Break Accumulation: A Dissertation
Pickering, M. (2006) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/h6jf-nf65
Balko, J. M. (2009) · UKnowledge (University of Kentucky)
Tian, K., Shen, Y., Luo, Y.-R., Wang, M., Liu, H., Zhao, H., & Zhang, L. (2006) · Chinese Journal of Cancer Research · doi:10.1007/s11670-006-0276-6
Caractérisation moléculaire de tumeurs pulmonaires radon-induites chez le rat
Guillet, K., & Bernaudin, J. (2008) · HAL
Cell cycle: mechanisms of control and dysregulation in cancer
Knudsen, E. S., Bourgo, R. J., Gosnell, E. L., Dean, J. L., & McClendon, A. K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.039
Raaphorst, F. M., Otte, A. P., van Lohuizen, M., & Leemans, C. R. (2008)
Squamous cell carcinoma of the lung
Flieder, D. B., & Brambilla, E. M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139018760.031
Lees, J. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50007-5
Bastide, K. (2009)
Molecular Basis of Neuroendocrine Prostate Cancer
Akamatsu, S. (2018) · Springer eBooks · doi:10.1007/978-981-10-7013-6_39
Gene Therapy and Oncolytic Viruses
McCormick, F. P., & Korn, W. M. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10056-1
Сочетание гамартомы и метастаза рака щитовидной железы в одной доле легкого
Podgornova, M. N., Алексеевна, Д. Е., & Щеголев, А. И. (2009) · PULMONOLOGIYA · doi:10.18093/0869-0189-2009-3-124-128
Tichelaar, J. W., & Leikauf, G. D. (2005) · CRC Press eBooks · doi:10.1201/9780203503430.ch15
Molecular Basis of Pulmonary Disease
Zander, D. S., & Farver, C. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00018-3
Retinoblastoma Tumor Suppressor Protein (RB)
Radulescu, R. T. (2017) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101891-2 · Cited by 1
Meisterernst, M. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1166540.627541
Retinoblastoma Tumor Suppressor Protein (RB)
Radulescu, R. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101891
Retinoblastoma Tumor Suppressor Protein (RB)
Radulescu, R. T. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101891-1 · Cited by 1
Sage, J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725829625.793552298
Research Advances in Neuroendocrine Prostate Cancer
刘, 雪. (2025) · Bioprocess · doi:10.12677/bp.2025.154031
Retinoblastoma-Proficient Small Cell Lung Cancer: A Novel Entity With Therapeutic Vulnerability?
Dowlati, A., Ferdousi, R., Ajay, A., Brewster, C., Grubb, B. J., Golya, A., Savari, O., Lam, M. C., & Wildey, G. M. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103714
Metadata
- Authors
- Kaye, F. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Kaye, Frederic J
- ORCID
- Kaye, Frederic J
- Venue
- Oncogene
- Published
- 2002-10-04
- Volume
- 21
- Issue
- 45
- Pages
- 6908-6914
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2081412587
- Cited by
- 153
- References
- 80
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 5 · 2014: 13 · 2013: 5 · 2012: 4
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- retinoblastoma protein, cyclin-dependent kinases, p16, tumor suppressor pathways, lung cancer, lung carcinogenesis, gene inactivation, epigenetic modifications, DNA tumor viruses, carcinogen exposure, targeted therapy
- MeSH terms
- Humans, Lung Neoplasms, Proto-Oncogene Proteins, Genes, Retinoblastoma, Gene Deletion, Carcinoma, Small Cell, Cyclin-Dependent Kinases, Genes, p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.